162 related articles for article (PubMed ID: 12543650)
1. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.
Adelson ME; Pacchia AL; Kaul M; Rando RF; Ron Y; Peltz SW; Dougherty JP
Antimicrob Agents Chemother; 2003 Feb; 47(2):501-8. PubMed ID: 12543650
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
3. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
5. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
Mayers DL
Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
[TBL] [Abstract][Full Text] [Related]
7. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
Ochsenbauer-Jambor C; Jones J; Heil M; Zammit KP; Kutsch O
Biotechniques; 2006 Jan; 40(1):91-100. PubMed ID: 16454046
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay.
Garcia JM; Gao A; He PL; Choi J; Tang W; Bruzzone R; Schwartz O; Naya H; Nan FJ; Li J; Altmeyer R; Zuo JP
Antiviral Res; 2009 Mar; 81(3):239-47. PubMed ID: 19118579
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
10. Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
Davis C; Heredia A; Le N; Dominique JK; Redfield RR
J Hum Virol; 2001; 4(3):113-22. PubMed ID: 11572234
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.
Hartman TL; Yang L; Helfrick AN; Hassink M; Shank NI; George Rosenker K; Scerba MT; Saha M; Hughes E; Wang AQ; Xu X; Gupta P; Buckheit RW; Appella DH
Antiviral Res; 2016 Oct; 134():216-225. PubMed ID: 27568924
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
13. [Screening of HIV-1 replication inhibitors by using pseudotyped virus system].
Cao YL; Guo Y
Yao Xue Xue Bao; 2008 Mar; 43(3):253-8. PubMed ID: 18630260
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.
Jellinger RM; Shafer RW; Merigan TC
J Infect Dis; 1997 Mar; 175(3):561-6. PubMed ID: 9041326
[TBL] [Abstract][Full Text] [Related]
15. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.
Thenin-Houssier S; de Vera IM; Pedro-Rosa L; Brady A; Richard A; Konnick B; Opp S; Buffone C; Fuhrmann J; Kota S; Billack B; Pietka-Ottlik M; Tellinghuisen T; Choe H; Spicer T; Scampavia L; Diaz-Griffero F; Kojetin DJ; Valente ST
Antimicrob Agents Chemother; 2016 Apr; 60(4):2195-208. PubMed ID: 26810656
[TBL] [Abstract][Full Text] [Related]
16. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
17. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1.
Junker U; Baker J; Kalfoglou CS; Veres G; Kaneshima H; Böhnlein E
AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1395-402. PubMed ID: 9359659
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Ferris RG; Hazen RJ; Roberts GB; St Clair MH; Chan JH; Romines KR; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Weaver KL; Selleseth DW; Moniri KR; Boone LR
Antimicrob Agents Chemother; 2005 Oct; 49(10):4046-51. PubMed ID: 16189079
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
20. A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
Moussazadeh M; Hua J; Sidhu MK; Zhao XX; Fitzgibbon JE; Liao MJ; Rashidbaigi A
Antiviral Res; 1999 Jul; 42(3):177-87. PubMed ID: 10443530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
